From epilepsy to depression to Alzheimer’s, neurological conditions affect almost everyone. And people are desperately seeking solutions for themselves or someone they love. The Neurosciences Medicine (NSM) research program at the DCRI is dedicated to taking bold action to find these solutions.
- DCRI faculty and staff recently presented their research at the American Academy of Neurology and World Intracranial Hemorrhage conferences.
NINDS Early Phase
- The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, has awarded a 10-year contract to Duke to design, manage, and conduct Phase I clinical trials for new drugs to treat neurological conditions such as Alzheimer’s disease and neuropathy. The trials will be conducted by DCRI Neurosciences faculty in conjunction with the DCRI’s Early Phase group.
- The Software Treatment for Actively Reducing Severity of ADHD (STARS-ADHD) study is examining whether a new digital intervention can benefit young patients with ADHD. The DCRI’s Scott Kollins, PhD, is leading the study.
Comprehensive Experience in Neuroscience Research
We conduct industry- and government-funded clinical projects of all sizes.
- Anxiety disorders
- Bipolar disorders
- Eating disorders
- Major depression
- Multiple sclerosis
- Neuromuscular disorders
- Tourette syndrome/obsessive-compulsive disorder
- Parkinson's disease
- Sleep disorders
- Substance abuse
- Traumatic brain injury
- Early-phase PK/PD and POC trials, conducted in our onsite phase I unit
- Game and device/sham-controlled trial design and conduct
- Pediatrics (microdosing, PK)
- Neurocritical care trials
- Nerve conduction studies and electromyography
- Immune monitoring: mechanistic and predictive biomarkers
- Translational studies
- Large multisite trials
- Full-service CRO activities (protocol design/development, data management, biostatistics, pharmacokinetics, site management/monitoring)
We Take Bold Steps in Neuroscience Medicine, Because Bold Solutions Are Needed
Driven by more than 40 psychiatry and neurology faculty, our program develops, conducts, and supports innovative phase I–IV clinical trials addressing neurological and psychiatric conditions for child, adolescent, adult, and geriatric patient populations.
Our Clinical Trials Experience
- Rapid-start site network for neurosciences trials
- Biomarker development
- Cognitive endpoint design and assessment in clinical trials
- Control intervention development
- FAST-FAIL trial methodology
- Inpatient ICU trials (TBI)
- Neuroimmunology biomarker imaging studies
- Novel trial designs
- RDOC-based research
Neurosciences Medicine Leadership
Andrew D. Krystal, MD, MS, is director of the DCRI’s Neurosciences Medicine Research Program, Krystal links multi center clinical trial expertise and resources with the strong translational neuroscience and intervention-development research capabilities of Duke University’s Department of Psychiatry and Behavioral Sciences. In addition to being a professor in that department, Krystal also serves as the director of the Duke Sleep Research Program and clinical director of the Brain Stimulation Program.
Daniel Laskowitz, MD, MHS, graduated from the Duke University School of Medicine. After completing his residency at Hospital of the University of Pennsylvania, he returned to Duke to complete his residency in cerebrovascular disease and neurocritical care. Laskowitz's research interests include exploring new therapeutic interventions in the clinical setting of stroke, intracranial hemorrhage, and closed head injury. He is committed to translational research, and has several active clinical research protocols designed to bring the research performed in the Multidisciplinary Research Laboratories to the clinical arena.
Faculty Profile: Scott Kollins, PhD, MS
Scott Kollins, Phd, MS, discusses his work at the DCRI as Global Lead for ADHD and Substance Use Disorders, and the Duke ADHD Program.